Comparable stake leader
Knight Therapeutics Inc.
SEC ownership of 60 DEGREES PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001946563.
Disclosed value leader
Knight Therapeutics Inc.
Comparable rows
15/31
Latest evidence
31 Jul 2026
- Public ticker
- SXTP, SXTPW on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Knight Therapeutics Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
15 of 31
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Knight Therapeutics Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001946563
- Issuer location
- Washington, DC
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of 60 DEGREES PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Knight Therapeutics Inc.
Disclosed value leader
Knight Therapeutics Inc.
Comparable rows
15/31
Latest evidence
31 Jul 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
16 rows are not safely comparable across share classes.
13D/G row: Knight Therapeutics Inc.
Showing 1-8 of 31 holder rows.
Quick read
Knight Therapeutics Inc. leads the comparable SEC ownership view at 20%.
15 of 31 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Knight Therapeutics Inc.'s linked filing trail.
Comparable ownership
Top 5
Knight Therapeutics Inc.
20%
INTRACOASTAL CAPITAL, LLC
9.1%
CVI Investments, Inc.
7%
Lind Global Fund III LP
5.4%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 31 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Knight Therapeutics Inc. |
3/4/5
13D/G
10%+ Owner
|
20%
from 13D/G
|
$6,324,872
1,891,329 shares
mixed-class rows
|
— | 22 Jul 2026 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
9.1%
|
$339,474
263,158 shares
|
-$248,179 | 31 Mar 2026 |
| CVI Investments, Inc. |
13D/G
|
7%
|
$255,305
197,911 shares
|
$0 | 31 Mar 2026 |
| Lind Global Fund III LP |
13D/G
|
5.4%
|
$277,778
191,571 shares
|
$0 | 31 Jul 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$226,656
77,357 shares
|
$0 | 31 Mar 2025 |
| Orca Capital AG |
13D/G
|
4.9%
|
$382,327
166,229 shares
|
$0 | 15 Jul 2025 |
| Ayrton Capital LLC |
13D/G
|
4.1%
|
$260,977
177,427 shares
|
+$20,515 | 30 Sep 2025 |
| Cheryl Xu |
3/4/5
Director
|
0.37%
|
$45,866
15,816 shares
|
— | 03 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$30,095.
Buys
$30,095
Insiders: 1
Sells
$0
Insiders: 0
Net
+$30,095
Shares: +29,983
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 29,983
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 7,350 | 0 | $10,131 | $0 | +$10,131 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 22,633 | 0 | $19,964 | $0 | +$19,964 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to 60 DEGREES PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Knight Therapeutics Inc.
Net 12M change
+$30,095
Latest report
22 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Knight Therapeutics Inc. | 10%+ Owner | $6,324,872 | Mixed | 22 Jul 2026 | ||
| KENTUCKY TECHNOLOGY INC. | 10%+ Owner | $196,875 | Mixed | 11 Jul 2023 | ||
| Florida State University Research Foundation Inc. | 10%+ Owner | $151,875 | Mixed | 11 Jul 2023 | ||
| Cheryl Xu | Director | $45,866 | Filing P/S | 03 Jun 2025 | ||
| Tyrone Miller | Cfo | $38,237 | Mixed | 17 Jan 2025 | ||
| Geoffrey S. Dow | President and CEO, Director | $33,262 | +$30,095 | +950% | Filing P/S | 12 Jun 2026 |
| Kristen Landon | Chief Operating Officer | $11,713 | Mixed | 17 Jan 2025 | ||
| Charles W. Allen | Director | $4,622 | Mixed | 31 Dec 2023 | ||
| Stephen Toovey | Director | $4,014 | Mixed | 31 Dec 2023 | ||
| Paul Field | Director | $4,014 | Mixed | 31 Dec 2023 | ||
| Bryan Lee Smith | Chief Medical Officer | Mixed | 11 Jul 2023 | |||
| Eric Francois | Director | Mixed | 13 May 2026 |
Recent insider transactions for 60 DEGREES PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 43.8% | $10,131 | $1.38 | 7,350 | 24,131 | 12 Jun 2026 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 19.4% | $7,759 | $0.8024 | 9,670 | 59,618 | 15 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 7.8% | $3,318 | $0.9184 | 3,613 | 49,948 | 11 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 25.3% | $8,886 | $0.9504 | 9,350 | 46,335 | 10 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Award | 27.5% | 7,201 | 33,372 | 12 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.